Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004897 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy and Interferon Alfa Followed by Surgery and/or Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer
A Phase 2 study, sponsored by Northwestern University.
- Terminated
- Registry status
- Phase 2
- Development phase
NCT00004897 is a Phase 2 study that was terminated before completion, run by Northwestern University.
The verdict
NCT00004897, a Phase 2 study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one drug and combining chemotherapy with interferon alfa, surgery, and/or radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy and interferon alfa followed by surgery and/or radiation therapy in treating patients who have stage I, stage II, or stage III esophageal cancer.
Interventions
- DRUG cisplatin
- DRUG fluorouracil
- DRUG leucovorin calcium
- BIOLOGICAL recombinant interferon alfa
- DRUG hydroxyurea
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-10 |
| Est. Completion | 2007-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004897
The ClinicalTrials.gov registry entry for NCT00004897 describes a study currently listed as terminated, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00004897 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004897 about?
NCT00004897 is a clinical study titled "Combination Chemotherapy and Interferon Alfa Followed by Surgery and/or Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one drug and combining chemother...
What is the current status of trial NCT00004897?
This trial is currently terminated. It is a Phase 2 study. The study started on 1999-10. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00004897?
The interventions under investigation include: cisplatin (DRUG), fluorouracil (DRUG), leucovorin calcium (DRUG), recombinant interferon alfa (BIOLOGICAL), hydroxyurea (DRUG).
Who is sponsoring clinical trial NCT00004897?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.